Melanoma Trial Tests Individualized Neoantigen Therapy at Scale

By Amara Osei

The phase 3 INTerpath-001 trial (NCT05933577) randomly assigned 1,137 patients with stage IIB to IV melanoma at 157 sites worldwide, evaluating intismeran autogene as an individualized neoantigen therapy for resectable disease intended to prevent recurrence. At the 2026 ESMO Congress, Georgina V. Long, AO, BSc, PhD, MBBS, described both the treatment-design process and the operational test embedded in the trial.

How is intismeran individualized?

Each cycle begins with the patient’s own tumor, according to Long. The workflow then moves through four steps:

• Sequence: Next-generation sequencing (NGS, a high-throughput method for reading DNA) identifies mutations present in the tumor but absent from the patient’s normal cells.
• Establish uniqueness: Long said those mutations are also absent from other patients’ cancers, producing a neoantigen list (mutation-derived targets) unique to the individual.
• Rank: Computational analysis predicts which candidate neoantigens may produce the strongest antitumor response. The ranking weighs clonality (how widely a mutation is shared across tumor cells), expression (how actively the corresponding gene is transcribed), and the patient’s major histocompatibility complex (MHC, antigen-presentation molecules) class I and class II profile.
• Build and administer: Up to 34 top-ranked neoantigens are encoded into a single synthesized messenger RNA (mRNA), packaged in a lipid nanoparticle that carries it, and injected into the patient.

This sequence turns a tumor-specific finding into an individualized mRNA construct. It also makes every step consequential: a failure at tissue acquisition, sequencing, computational selection, or production can stop the pathway before injection. The account does not quantify those failure points or provide a contingency process.

What does the 157-site trial test?

INTerpath-001 combines a large randomized cohort with broad geography. Long said enrollment was among the fastest she has seen. In her assessment, that pace addresses whether “a fully individualized therapy can be delivered at a global scale.”

The reported interval from tumor tissue to injection was about 6 to 8 weeks. That window places the entire bespoke workflow on a defined clock. The interview provides no time allocation for individual steps, so the figure does not demonstrate that every site will achieve the same turnaround.

Long identified the main treatment-site challenge as “providing enough tumor tissue for NGS.” The constraint is therefore upstream of the delivery system: each patient must supply an adequate sample, and the center must coordinate with pathology (the tissue-analysis department) to provide it. Sequencing capacity alone cannot resolve that dependency.

Long does not expect tissue availability to become a major obstacle for oncologists. She noted that tissue requirements have grown steadily over the past 2 decades and that clinicians have repeatedly adapted, while institutions are accustomed to solving similar logistical problems. Her qualification is important: the work still depends on site infrastructure, particularly pathology coordination. She identifies this as the area needing attention as the therapy moves forward.

What do the data still need to show?

The interview leaves four decisive elements unstated:

• Recurrence outcomes: No result is reported for the trial’s stated aim of preventing recurrence.
• Comparative benefit: The account does not identify a comparator or the allocation ratio (how participants were distributed among study arms).
• Safety and dose: Neither is provided.
• Regulatory status: No approval decision is described.

These omissions matter because the proposed clinical purpose is recurrence prevention, whereas the material presented establishes a production workflow and a level of trial reach rather than a treatment benefit. The 1,137-patient cohort and 6- to 8-week interval support the claim that intismeran autogene can be manufactured and administered at scale under study conditions. They do not establish that the approach changes outcomes, and “scale” describes operational capacity, not comparative efficacy. That distinction matters if safety findings prove favorable, because approval would still require evidence of efficacy.

What must happen before approval?

Long expects health authorities around the world to examine and scrutinize INTerpath-001 data, with each authority deciding whether to approve intismeran autogene. She said approval of the therapy is intended to bring a new level of targeted therapy to patients with cancer. The global trial therefore creates a second challenge after manufacturing: regulators must evaluate the same individualized approach under their own review processes.

The next decisive evidence will come from the trial’s clinical results and the regulatory reviews, not enrollment numbers alone. If the data support recurrence prevention and authorities authorize the approach, the remaining test will be whether a bespoke treatment can enter routine care while preserving adequate tissue sampling and the reported 6- to 8-week pathway.